hVIVO (LSE:HVO) has been awarded a contract by ILiAD Biotechnologies to conduct what is set to be the world’s first pivotal Phase III human challenge study for a whooping cough vaccine. The trial will evaluate ILiAD’s intranasal candidate, BPZE1, against the current Tdap vaccine standard. Expected to enrol more than 500 participants through FluCamp, the study will be the largest human challenge trial ever undertaken by hVIVO and will be supported by its specialist bacterial laboratory in Canary Wharf.
The multi-year agreement is anticipated to begin contributing revenue in the first half of 2026, with the majority of income recognised across 2026 and 2027. This contract is expected to provide a meaningful uplift to both near- and medium-term revenues. Management noted that the project highlights increasing regulatory acceptance of human challenge trials as a faster pathway to generating pivotal efficacy data, potentially reinforcing hVIVO’s competitive position while accelerating vaccine development for diseases with unpredictable transmission patterns, such as whooping cough.
Despite this significant contract win, the company’s broader outlook remains constrained by ongoing losses, substantial cash burn, and concerns around liquidity and forward visibility, as flagged in recent earnings commentary. Technical indicators point to a supportive upward trend, although overbought signals suggest some caution in the near term. Valuation continues to be pressured by negative earnings and the suspension of dividend payments.
More about hVIVO plc
hVIVO plc is a specialist clinical development company and a global leader in human challenge trials, partnering with seven of the world’s ten largest biopharmaceutical firms. The group provides a full-service platform spanning early-stage strategy through to Phase II trials, supported by its own clinical facilities, laboratories, and its FluCamp volunteer recruitment arm operating across the UK and Germany.
Leave a Reply